Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
Alexander Drilon(Memorial Sloan Kettering Cancer Center), Salvatore Siena(University of Milan), Rafał Dziadziuszko(Gdańsk Medical University), Fabrice Barlési(Centre National de la Recherche Scientifique), Matthew Krebs(Manchester Academic Health Science Centre), Alice T. Shaw(Massachusetts General Hospital), Filippo de Braud(University of Milan), Christian Rolfo(University of Maryland, Baltimore), Myung‐Ju Ahn(Samsung Medical Center), Jürgen Wolf(University Hospital Cologne), Takashi Seto(National Hospital Organization Kyushu Cancer Center), Byoung Chul Cho(Yonsei University), Manish R. Patel(University of Minnesota), Chao‐Hua Chiu(Taipei Veterans General Hospital), Thomas John(Olivia Newton-John Cancer Wellness & Research Centre), Kōichi Goto(National Cancer Center Hospital East), Christos S. Karapetis(Flinders University), Hendrick-Tobias Arkenau(Sarah Cannon Research Institute), Sang-We Kim(Ulsan College), Yuichiro Ohe(Tokyo National Hospital), Yu Li, Young Kwang Chae(Northwestern University), Christine H. Chung(Moffitt Cancer Center), Gregory A. Otterson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Haruyasu Murakami(Shizuoka Cancer Center), Chia‐Chi Lin(National Taiwan University Hospital), Daniel Shao-Weng Tan(National Cancer Centre Singapore), Hans Prenen(Antwerp University Hospital), Todd Riehl, Edna Chow‐Maneval(Ignyta (United States)), Brian Simmons, Na Cui, Ann Johnson(Ignyta (United States)), Susan Eng, Timothy R. Wilson, Robert C. Doebele(University of Colorado Anschutz Medical Campus)
Cited by 533Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis